Doctors Offer New Treatment Of Parkinson's Disease

Doctors Offer New Treatment Of Parkinson's Disease.
A routine nutritional complement called inosine safely boosts levels of an antioxidant thought to ease people with Parkinson's disease, a small new study says. Inosine is a forerunner of the antioxidant known as urate. Inosine is simply converted by the body into urate, but urate taken by mouth breaks down in the digestive system. "Higher urate levels are associated with a lop off risk of developing Parkinson's disease, and in Parkinson's patients, may discuss a slower rate of disease worsening," explained Dr Andrew Feigin, a neurologist at the Cushing Neuroscience Institute's Movement Disorders Center in Manhasset, NY He was not connected to the supplementary study.

The swotting included 75 people who were newly diagnosed with Parkinson's and had crestfallen levels of urate. Those who received doses of inosine meant to push up urate levels showed a rise in levels of the antioxidant without suffering serious side effects, according to the lessons published Dec 23, 2013 in the journal JAMA Neurology. "This enquiry provided clear evidence that, in people with early Parkinson disease, inosine care can safely elevate urate levels in the blood and cerebrospinal fluid for months or years," swatting principal investigator Dr Michael Schwarzschild, a neurologist at Massachusetts General Hospital, said in a sanitarium news release.

And "We know that urate has neuroprotective properties in animal models". Several forgiving trials had also hinted that it might help Parkinson's patients "so the positive results of this distress are very encouraging". The findings support further research into urate's ability to slow the intensification of Parkinson's, and Schwarzschild and his team are designing a larger phase 3 clinical trial.

However, notwithstanding the positive results so far, Parkinson's patients and their caregivers should not attempt inosine treatment at this while who is also a professor of neurology at Harvard Medical School. "While there is considerable evidence to support this therapy's potential, inosine is still an unproven healing for Parkinson disease," he said "We know that excessively capital urate can lead to kidney stones, gout and possibly other untoward effects, which is why attempts to elevate urate are best pursued in carefully designed clinical trials where the risks can be reduced and balanced against achievable benefits".

One other masterful agreed that more study is needed. "As a phase 2 study, this or code was not designed to demonstrate whether or not treatment with inosine delayed need for symptomatic therapy for Parkinson's disease," said Dr Steven Frucht, a professor of neurology and administrator of the movement disorders split at Mount Sinai School of Medicine, in New York City stories. "A development 3 trial will be needed to demonstrate whether or not oral inosine helps fight Parkinson's, or even has the capability to delay the need for symptomatic treatment".